Antiplatelet drugs

British Journal of Pharmacology

Volumn 147, Issue SUPPL. 1, 2006, Pages

  Born, Gustav ^a   Patrono, Carlo ^b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aspirin; Dipyridamole; GPIIb IIIa antagonists; Platelet aggregation; Thienopyridines

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; ORBOFIBAN; PYRIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; SALICYLATE SODIUM; SIBRAFIBAN; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

ACETYLATION; BIOCHEMISTRY; BLEEDING; BLOOD CLOTTING; CARDIOTOXICITY; CLINICAL TRIAL; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG EFFICACY; HUMAN; METABOLISM; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; SAFETY; THROMBOCYTE;

ANIMALS; ASPIRIN; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DIPYRIDAMOLE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; THROMBOSIS;

EID: 30444454823     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706401     Document Type: Review

References (52)

1. BORN, G.V.R. (1962a). Quantitative investigations into the aggregation of blood platelets. J. Physiol., 162, 7-68.
2. BORN, G.V.R. (1962b). Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (London), 194, 927-929.
3. BORN, G.V.R. (1964). Strong inhibition by 2-chloroadenosine of the aggregation of blood platelets by adenosine diphosphate. Nature (London), 202, 95-96.
4. BORN, G.V.R. (1965). Platelets in thrombogenesis: mechanisms and inhibition of platelet aggregation. Ann. Roy. Coll. Surg. Engl., 36, 200-206.
5. BORN, G.V.R. (1970). Observations on the change in shape of blood platelets brought about by adenosine diphosphate. J. Physiol., 209, 487-511.
6. BORN, G.V.R. & CROSS, M.J. (1962). Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J. Physiol., 166, 29-30.
7. BORN, G.V.R. & CROSS, M.J. (1963). The aggregation of blood platelets. J. Physiol., 168, 179-195.
8. BORN, G.V.R. & CROSS, M.J. (1964). Effects of inorganic ions and of plasma proteins on the aggregation of blood platelets by adenosine diphosphate. J. Physiol., 170, 397-414.
9. BORN, G.V.R., DEARNLEY, R., FOULKS, J.G. & SHARP, D.E. (1978). Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J. Physiol., 280, 193-212.
10. BORN, G.V.R., HASLAM, R.J., GOLDMAN, M. & LOWE, R.D. (1965). Comparative effectiveness of adenosine analogues as inhibitors of blood platelet aggregation and as vasodilators in man. Nature (London), 205, 678-680.
11. BORN, G.V.R., HONOUR, A.J. & MITCHELL, J.R.A. (1964). Inhibition by adenosine and by 2-chloroadenosine of the formation and embolisation of platelet thrombi. Nature (London), 202, 761-765.
12. BORN, G.V.R. & HUME, M. (1967). Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature (London), 215, 1027-1029.
13. BORN, G.V.R. & MILLS, D.C.B. (1969). Potentiation of the inhibiting effect of adenosine by drugs that prevent its uptake. J. Physiol. (London), 202, 41-42.
14. BUNAG, R.D., DOUGLAS, C.R., IMAI, S. & BERNE, R.M. (1964). Influence of a pyrimidopyrimidine derivative on deamination of adenosine by blood. Circ. Res., 15, 83-88.
15. 2 but not systemic prostacyclin by controlled release aspirin. N. Engl. J. Med., 325, 1137-1141.
16. CLAYTON, S., BORN, G.V.R. & CROSS, M.J. (1963). Inhibition of the aggregation of blood platelets by nucleotides. Nature (London), 200, 138-139.
17. COLLER, B.S. (1995). Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation, 92, 2373-2380.
18. COLLER, B.S., PEERSCHKE, E.I., SCUDDER, L.E. & SULLIVAN, C.A. (1983). A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds of glycoproteins IIb and/or IIIa. J. Clin. Invest., 72, 325-338.
19. CROSS, M.J. (1964). Effect of fibrinogen on the aggregation of platelets by adenosine diphosphate. Thromb. Diath. Haemorrh., 12, 524-527.
20. EL KOUNI, M.H. (2003). Potential cheraotherapeutic targets in the purine metabolism of parasites. Pharmacol. Therap., 99, 283-309.
21. EVANS, G., PACKHAM, M.A., NISHIZAWA, E.E., MUSTARD, J.F. & MURPHY, E.A. (1968). The effect of acetylsalicylic acid on platelet function. J. Exp. Med., 128, 877-894.
22. FERREIRA, S.H., MONCADA, S. & VANE, J.R. (1971). Indomethacin and aspirin abolish prostaglandin release from spleen. Nat. New Biol., 231, 237-239.
23. FITZGERALD, G.A. (2004). Coxibs and cardiovascular disease. N. Engl. J. Med., 351, 2875-2878.
24. FITZGERALD, G.A., BRASH, A.R., FALARDEAU, P. & OATES, J.A. (1981). Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest., 68, 1271-1276.
25. FITZGERALD, G.A., OATES, J.A., HAWIGER, J., MAAS, R.L., ROBERTS II, L.J., LAWSON, J.A. & BRASH, A.R. (1983). Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest., 71, 676-688.
26. HAMBERG, M., SVENSSON, J. & SAMUELSSON, B. (1975). Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Nat. Acad. Sci. U.S.A., 72, 2994-2998.
27. HAWKINS, D., PINKARD, R.N., CRAWFORD, I.P. & FARR, R.S. (1969). Structural changes in human serum albumin induced by ingestion of acetylsalicylic acid. J. Clin. Invest., 48, 536-542.
28. ISIS-2 COLLABORATIVE GROUP (1988). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2, 349-360.
29. JAMES, D.M & BORN, G.V.R. (1980). Uptake of purine bases and nucleotides in African trypanosomes. Parasitology, 81, 383-393.
30. LANDOLFI, R., MARCHIOLI, R., KUTTI, J., GISSLINGER, H., TOGNONI, G., PATRONO, C. & BARBUI, T. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med., 350, 114-124.
31. LATIMER, P., BORN, G.V.R. & MICHAL, F. (1977). Application of light-scattering theory to the optical effects associated with the morphology of blood platelets. Arch. Biochem. Biophys., 180, 151-159.
32. MACMILLAN, D.C. & OLIVER, M.F. (1965). The initial changes in platelet morphology following the addition of adenosine diphos-phate. J. Atheroscler Res., 5, 440-444.
33. MICHAL, F. & BORN, G.V.R. (1971). Effect of the rapid shape change of platelets on the transmission and scattering of light through plasma. Nature (New Biol.), 231, 220-222.
34. MILLS, D.C.B., ROB, I.A. & ROBERTS, G.C.K. (1968). The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J. Physiol., 195, 715-729.
35. MONCADA, S., GRYGLEWSKI, R., BUNTING, S. & VANE, J.R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (London), 263, 663-665.
36. MONCADA, S. & VANE, J.R. (1979). Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N. Engl. J. Med., 300, 1142-1147.
37. O'BRIEN, J.R. (1968). Effects of salicylates on human platelets. Lancet, 1, 779-783.
38. PATRIGNANI, P., FILABOZZI, P. & PATRONO, C. (1982). Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest., 69, 1366-1372.
39. PATRONO, C., CIABATTONI, G., PINCA, E., PUGLIESE, F., CASTRUCCI, G., DE SALVO, A., SATTA, M.A. & PESKAR, B.A. (1980). Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res., 17, 317-327.
40. PATRONO, C., CIABATTONI, G., PUGLIESE, F., PIERUCCI, A., BLAIR, I.A. & FITZGERALD, G.A. (1986). Estimated rate of thromboxane secretion into the circulation of normal man. J. Clin. Invest., 77, 590-594.
41. PATRONO, C., COLLER, B., FITZGERALD, G.A., HIRSH, J. & ROTH, G. (2004). Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 126, 234S-264S.
42. PEDERSEN, A.K. & FITZGERALD, G.A. (1984). Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclo-oxygenase. N. Engl. J. Med., 311, 1206-1211.
43. REILLY, I.A.G. & FITZGERALD, G.A. (1987). Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 69, 180-186.
44. RICHARDSON, P.D., GALLETTI, P.M. & BORN, G.V.R. (1976). Regional administration of drugs to control thrombosis in artificial organs. Trans. Am. Soc. Artif. Int. Organs, 22, 22-29.
45. 2 in man. Identification of twenty urinary metabolites. J. Biol. Chem., 256, 8384-8393.
46. ROTH, G.J. & MAJERUS, P.W. (1975). The mechanism of the effect of aspirin on human platelets. Acetylation of a particulate fraction protein. J. Clin. Invest., 56, 624-632.
47. ROTH, G.J., STANFORD, N. & MAJERUS, P.W. (1975). Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U.S.A., 72, 3073-3076.
48. SMITH, J.B. & WILLIS, A.L. (1971). Aspirin selectively inhibits prostaglandin production in human platelets. Nat. New Biol., 231, 235-237.
49. VANE, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231, 232-235.
50. WEISS, H.J. & ALEDORT, L.M. (1967). Impaired platelet-connective- tissue reaction in man after aspirin ingestion. Lancet, 2, 495-497.
51. WEISS, H.J., ALEDORT, L.M. & KOCHWA, S. (1968). The effect of salicylates on the hemostatic properties of platelets in man. J. Clin. Invest., 47, 2169-2180.
52. WEYRICH, A.S., DENIS, M.M., KUHLMANN-EYRE, J.R., SPENCER, E.D., DIXON, D.A., MARATHE, G.K., MCINTYRE, T.M., ZIMMERMAN, G.A. & PRESCOTT, S.M. (2005). Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation, 111, 633-642.